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Table 1. Sample description
Age M/F Urban/Rural Marital Status
Mean, sd (with partner/alone)
Group 1
(n=23) 58.7, 11.0 7/16 (30.4/69.5%) 12/11 (52.2/47.8%) 8/15 (34.8/65.2%)
Group 2
(n=49) 62.6, 9.3 9/40 (18.4/81.6%) 24/25 (49.0/51.0%) 14/35 (28.6/71.4%)
Group 3
(n=22) 63.0, 9.9 4/18 (18.2/81.8) 15/7 (68.2/31.3%) 8/14 (36.4/63.6%)
Table 2. Pain, Disability and Participation
Group 1 (n=23) Group 2 (n=49) Group 3 (n=22)
mean (95% CI) mean (95% CI) mean (95% CI)
Constant Pain 14.6 (2.1-27.0) 25.1 (17.0-33.2) 25.7 (10.2-41.1)
Intermittent Pain 29.7 (20.8-38.6) 35.8 (28.4-43.2) 47.0 (34.9-59.0)
Total Pain 22.8 (17.5-28.1) 30.9 (26.2-35.6) 37.3 (28-46.5)
NRS Pain 5.1 (4.1-6.1) 5.5 (5.0-6.1) 6.9 (5.8-7.9)
KOOS-PS 38.4 (31.0-45.7) 48.6 (45.2-52.1) 46.1 (41.1-51.1)
KOOS-ADL 68.7 (59.8-77.7) 58.1 (53.2-63.0) 56.0 (47.6-64.4)
SRPQ: Importance 3.6 (3.4-3.8) 3.6 (3.5-3.7) 3.8 (3.1-4.5)
SRPQ: Ability 3.1 (2.6-3.5) 3.1 (2.9-3.3) 2.6 (2.2-3.1)
those with early OA, 21% (5/23) intermittently used prescription
medication, 65% used over the counter medication and 22% used
glucosamine.
Conclusions: People with early OA experience pain and disability
although the trend is to a lesser degree than for those with mod-
erate and end-stage OA, as expected. A proportion of individuals
are seeking care. However, although the sample is small, these
data highlight the need for a better understanding of this subgroup
of people with early OA related to possible disease progression
and interventions to ameliorate symptoms and disability.
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Background: Results of clinical trials in OA are usually reported
as group comparisons of the mean (± standard deviation, sd) in
score of the selected outcome. It might be more clinically relevant
to show the results at a patient level, using a response criterion.
Several response criteria are available: OARSI/OMERACT modi-
ﬁed set of responder criteria [1], the Patient Acceptable Symptom
State (PASS) [2] and the Minimum Clinically Important Improve-
ment (MCII) [3].
Objectives: To assess differences in responder rates using vari-
ous response criteria in a RCT in knee OA.
Methods: Data were extracted from a prospective, multicentre,
double-blind RCT comparing two hyaluronans over 24 weeks
(F60027-Structovial and Hylan G-F 20-Synvisc) according to a
Abstract 304 – Table 1. Responder rates according to various deﬁnitions of response in a RCT in knee OA
PP dataset F60027 group Hylan G F-20 group Global population
Baseline pain score (0-100, mm) (sd) 68.6 (13.2) 67.5 (11.6) 68.1 (12.5)
Mean change from baseline at week 24 (mm) (sd) -38.8 (24.7) -37.1 (25.4) -38.0 (25.0)
N (%) of patients at PASS for pain at week 24 ≤32.3 mm 71 (59.7%) 78 (66.7%) 149 (63.1%)
N (%) of patients achieving MCII(absolute) on pain at week 24≥ 19.9 mm 96 (80.7%) 88 (75.2%) 184 (78%)
N (%) of patients achieving MCII (%) on pain at week 24 ≥40.8% improvement 83 (69.7%) 83 (70.9%) 166 (70.3%)
OMERACT/OARSI response criteria 77 (64.7%) 79 (67.5%) 156 (66%)
Baseline LFI score 13.6 (3.2) 13.2 (2.9) 13.4 (3.1)
Mean LFI score change from baseline at week 24 -5.7 (3.8) -5.6 (4.0) -5.7 (3.9)
non inferiority design. The main outcome was the Lequesne index
score (LFI). The secondary outcome was global pain on a Visual
Analog Scale (VAS). 236 patients were available in the main
analysis (per protocol analysis, PP). Demographic and knee OA
characteristics were identical to those usually reported in knee OA
trials. Since no value of the PASS is validated for the LFI yet, the
results on pain VAS were used to classify patients as responders
or not using OMERACT/OARSI modiﬁed criteria, PASS and MCII
(using absolute value or % of improvement). Results are reported
as mean (sd) and number (%).
Results: Table 1 below shows the response rates according to
the different criteria. Rates of responders varied considerably:
from 60 to 80% in each group and from 63% to 78% in the
overall population (both treatment groups can be merged since
non-inferiority was proven). The most liberal deﬁnition seems to
be MCII (absolute), while the strictest appears to be PASS.
Conclusions: Reporting clinical trial results at a patient level using
response rates might be meaningful in knee OA. However this
study clearly demonstrate that results signiﬁcantly vary according
to the response criterion used which is likely to lead to "positive"
or "negative" results accordingly. More work is needed to help
assessing the most clinically relevant response deﬁnition in knee
OA.
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Purpose: Fears and beliefs of patients are well identiﬁed in low
back pain patients but not usually taken into consideration for
management strategies and their assessment in OA. To identify
fears and beliefs of patients regarding knee OA management and
to develop a questionnaire assessing fears and beliefs of patients.
Methods: A qualitative study based on semi structured interviews
was performed with a stratiﬁed sample of 81 patients (59 women)
and 29 practitioners (8 women, 11 general practitioners (GPs),
6 rheumatologists, 4 orthopedic surgeons, 8 (4 GPs) delivering
alternative medicine). Eleven independent experts analyzed the
